Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livitol-17 in Alcoholic Liver Disease
NCT03503708Not yet recruiting
- Sponsor
- Composite Interceptive Med-Science Laboratories
- Start
- May 2018
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Composite Interceptive Med-Science Laboratories. Primary endpoints: Aspartate Aminotransferase at 3 months, Alanine Aminotransferase at 3 months and 4 more. Planned start May 2018; status: not yet recruiting.
Beyond the preview
Go deeper on NCT03503708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503708.